Rewarding properties of 1-benzylpiperazine, a new drug of abuse, in rats

被引:26
作者
Meririnne, E [1 ]
Kajos, M [1 ]
Kankaanpää, A [1 ]
Seppälä, T [1 ]
机构
[1] Natl Inst Publ Hlth, De4pt Mental Hlth & Alcohol Res, Drug Res Unit, FIN-00300 Helsinki, Finland
关键词
D O I
10.1111/j.1742-7843.2006.pto_243.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1-Benzylpiperazine (also known as 'Legal X', 'Legal E', or 'A2') is a psychoactive compound increasingly encountered on the clandestine market. Previous experimental data suggest that the compound possesses addictive properties. In the present study, we used the conditioned place preference method in the rat to test whether 1-benzylpiperazine possesses rewarding properties. Furthermore, the mechanisms of the 1-benzylpiperazine reward were investigated using selected dopamine and serotonin receptor antagonists. 1-Benzylpiperazine (1.25, 5, and 20 mg/kg) induced dose-dependently place preference. This place preference was attenuated by the antagonists SCH23390 (0.2 mg/kg; dopamine D1-like receptors) and MDL72222 (1.0 mg/kg; serotonin3 receptors), but not by raclopride (0.8 mg/kg; dopamine D2-like receptors) or ketanserin (2 mg/kg; preferentially serotonin2 receptors). Our results show that 1-benzylpiperazine possesses rewarding properties in the rat, which suggests the compound to be susceptible to human abuse. The brain dopaminergic and serotonergic systems appear to be involved in the 1-benzylpiperazine reward.
引用
收藏
页码:346 / 350
页数:5
相关论文
共 31 条
[1]   REWARD AND REINFORCEMENT PRODUCED BY DRINKING-WATER - ROLE OF OPIOIDS AND DOPAMINE-RECEPTOR SUBTYPES [J].
AGMO, A ;
FEDERMAN, I ;
NAVARRO, V ;
PADUA, M ;
VELAZQUEZ, G .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1993, 46 (01) :183-194
[2]   Fatal brain oedema after ingestion of ecstasy and benzylpiperazine [J].
Balmelli, C ;
Kupferschmidt, H ;
Rentsch, K ;
Schneemann, M .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2001, 126 (28-29) :809-811
[3]   Neuropharmacological mechanisms of drug reward: Beyond dopamine in the nucleus accumbens [J].
Bardo, MT .
CRITICAL REVIEWS IN NEUROBIOLOGY, 1998, 12 (1-2) :37-67
[4]   N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy') [J].
Baumann, MH ;
Clark, RD ;
Budzynski, AG ;
Partilla, JS ;
Blough, BE ;
Rothman, RB .
NEUROPSYCHOPHARMACOLOGY, 2005, 30 (03) :550-560
[5]   THE D-1 DOPAMINE RECEPTOR ANTAGONIST SCH 23390 ALSO INTERACTS POTENTLY WITH BRAIN-SEROTONIN (5-HT2) RECEPTORS [J].
BISCHOFF, S ;
HEINRICH, M ;
SONNTAG, JM ;
KRAUSS, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 129 (03) :367-370
[6]  
Bourne JA, 2001, CNS DRUG REV, V7, P399
[7]   COMPARISON OF EFFECTS OF DEXAMPHETAMINE AND 1-BENZYLPIPERAZINE IN FORMER ADDICTS [J].
CAMPBELL, H ;
CLINE, W ;
EVANS, M ;
LLOYD, J ;
PECK, AW .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1973, 6 (03) :170-176
[8]  
CARR GD, 1989, NEUROPHARMACOLOGICAL, P265
[9]   ACTIVATION OF 5-HT3 RECEPTOR BY 1-PHENYLBIGUANIDE INCREASES DOPAMINE RELEASE IN THE RAT NUCLEUS-ACCUMBENS [J].
CHEN, J ;
VANPRAAG, HM ;
GARDNER, EL .
BRAIN RESEARCH, 1991, 543 (02) :354-357
[10]   Piperazine-like compounds:: a new group of designer drugs-of-abuse on the European market [J].
de Boer, D ;
Bosman, IJ ;
Hidvégi, E ;
Manzoni, C ;
Benkö, AA ;
dos Reys, LJAL ;
Maes, RAA .
FORENSIC SCIENCE INTERNATIONAL, 2001, 121 (1-2) :47-56